 EMERYVILLE, Calif., July 15, 2021 GLOBE NEWSWIRE -- XOMA Corporation NASDAQ: XOMA, announced today it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals vidutolimod CMP-001, an advanced-generation Toll-like receptor 9 agonist packaged in a virus-like particle, for 7.0 million upfront plus sales milestones. Vidutolimod is designed to trigger the bodys innate immune system to attack tumors in combination with other therapies. The U.S. Food and Drug Administration has granted Fast Track designation to vidutolimod for the treatment of certain types of metastatic or unresectable melanoma and an Orphan Drug designation for Stages IIb - IV melanoma. 